TMDX vs UNH

Transmedics (TMDX) retains its strong position in the organ transplantation market, powered by its proprietary Organ Care System (OCS) and expanding regulatory approvals, including the recent OCS Liver label expansion. The company posted robust FY25 revenue growth of 37% YoY, achieving its first year of GAAP profitability. Its deep competitive moat, built on advanced technology, extensive clinical...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...